Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial assessing emricasan for treatment for bacterial skin infections

Next Previous
Search
Trial Profile

A clinical trial assessing emricasan for treatment for bacterial skin infections

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emricasan (Primary)
  • Indications Bacterial infections; Bacterial skin diseases; Skin infections
  • Focus Adverse reactions

    • Most Recent Events

    • 20 Apr 2023 According to a Histogen media release, following notice from FDA related to company's recently filed IND, company is looking forward for anticipated initiation of clinical development activities using emricasan for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in the second half of 2023.
    • 09 Mar 2023 According to a Histogen media release, the company anticipate initiating clinical development activities for the treatment of ABSSSI in the first half of 2023.
    • 05 Jan 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top